SETH LERNER to Disease Progression
This is a "connection" page, showing publications SETH LERNER has written about Disease Progression.
Connection Strength
1.161
-
Strategies to prevent progression of high-risk bladder cancer at initial diagnosis. Curr Opin Urol. 2012 Sep; 22(5):405-14.
Score: 0.263
-
Molecular Subtypes of Non-muscle Invasive Bladder Cancer. Cancer Cell. 2016 07 11; 30(1):1-3.
Score: 0.086
-
Editorial comment. J Urol. 2010 Jul; 184(1):79-80.
Score: 0.057
-
The use and abuse of data: nomograms and talking to patients about clinical medicine. Urol Oncol. 2007 Jul-Aug; 25(4):333-7.
Score: 0.046
-
Chemoprevention of bladder cancer. World J Urol. 2006 Nov; 24(5):445-72.
Score: 0.044
-
Treatment of high-risk, non-muscle-invasive bladder cancer. Nat Clin Pract Urol. 2006 Aug; 3(8):398-9.
Score: 0.043
-
p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004 Mar 15; 22(6):1014-24.
Score: 0.036
-
Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol. 2003 Dec; 170(6 Pt 1):2248-52.
Score: 0.036
-
Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol. 2003 Sep; 170(3):985-9.
Score: 0.035
-
Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003 Jun; 61(6):1140-5.
Score: 0.035
-
Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int J Radiat Oncol Biol Phys. 2001 Sep 01; 51(1):16-22.
Score: 0.031
-
E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol. 2001 May; 165(5):1473-9.
Score: 0.030
-
E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001 Jan; 57(1):60-5.
Score: 0.029
-
Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res. 2001 Jan-Feb; 21(1B):575-8.
Score: 0.029
-
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
Score: 0.029
-
Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000 Nov 01; 56(5):735-40.
Score: 0.029
-
Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. Clin Cancer Res. 1999 Sep; 5(9):2520-5.
Score: 0.027
-
Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. Urol Oncol. 2019 07; 37(7):430-436.
Score: 0.026
-
Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol. 1999 Feb; 161(2):500-4.
Score: 0.026
-
Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study. Am J Clin Nutr. 2018 02 01; 107(2):208-216.
Score: 0.024
-
Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. Int J Cancer. 2018 05 01; 142(9):1797-1804.
Score: 0.024
-
Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. Sci Rep. 2017 01 19; 7:40714.
Score: 0.022
-
Positive association of collagen type I with non-muscle invasive bladder cancer progression. Oncotarget. 2016 Dec 13; 7(50):82609-82619.
Score: 0.022
-
Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. Eur Urol. 2015 Aug; 68(2):238-53.
Score: 0.020
-
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013 Jan; 63(1):45-57.
Score: 0.016
-
The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010 Sep 01; 16(17):4461-7.
Score: 0.014
-
Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU Int. 2009 May; 103(10):1359-62.
Score: 0.013
-
Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. BJU Int. 2008 Jun; 101(11):1356-61.
Score: 0.012
-
Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol. 2006 Jun; 175(6):2048-53; discussion 2053.
Score: 0.011
-
Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol. 2005 Aug 20; 23(24):5746-56.
Score: 0.010
-
Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission. Leukemia. 2002 Apr; 16(4):632-5.
Score: 0.008
-
High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res. 2001 Apr; 7(4):795-9.
Score: 0.007
-
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001 Mar 01; 19(5):1414-20.
Score: 0.007
-
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001 Jan 01; 97(1):256-63.
Score: 0.007
-
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998 Aug 15; 92(4):1165-71.
Score: 0.006